Professur für Endokrinologie

Ulmenweg 18
91054 Erlangen

Publications (Download BibTeX)

Go to first page Go to previous page 1 of 3 Go to next page Go to last page

Fehrenbach, U., Kahn, J., Fahlenkamp, U., Baur, A., Pavel, M.E., Geisel, D., & Denecke, T. (2019). Optimized imaging of the lower abdomen and pelvic region in hepatocyte-specific MRI: evaluation of a whole-abdomen first-pass shuttle protocol in patients with neuroendocrine neoplasms. Acta Radiologica, 60(9), 1074-1083.
Felder, S., Jann, H., Arsenic, R., Denecke, T., Prasad, ., Knappe-Drzikova, B.,... Pape, U.F. (2019). Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocrine-Related Cancer, 26(9), 751-763.
Yao, J., Garg, A., Chen, D., Capdevila, J., Engstrom, P., Pommier, R.,... Kulke, M.H. (2019). Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocrine-Related Cancer, 26(4), 391-403.
Pavel, M.E., Phan, A.T., Wolin, E.M., Mirakhur, B., Liyanage, N., Pitman Lowenthal, S.,... Vinik, A.I. (2019). Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist, 24(4), 463-474.
Semrau, S., Agaimy, A., Pavel, M.E., Lubgan, D., Schmidt, D., Cavallaro, A.,... Fietkau, R. (2019). Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: A case report. Journal of Medical Case Reports, 13(1).
Anthony, L., Kulke, M., Caplin, M., Bergsland, E., Oberg, K., Pavel, M.E.,... Jiang, W. (2019). Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials. In PANCREAS (pp. 428-428). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Thürauf, N., Bachlechner, S., Denzer-Lippmann, M., Wielopolski, J., Fischer, M., Büttner, A.,... Kornhuber, J. (2019). Grehlin concentrations correlate with hunger and craving ratings following oral ingestion of macronutrients. In CHEMICAL SENSES (pp. E55-E56). OXFORD: OXFORD UNIV PRESS.
Pavel, M.E., Dromain, C., Thanh, T.X.M., & Houchard, A. (2019). Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study. In NEUROENDOCRINOLOGY (pp. 157-157). BASEL: KARGER.
Schöfl, C., Mayr, B., Maison, N., Beuschlein, F., Meyer, G., Badenhoop, K.,... Quinkler, M. (2019). Daily adjustment of glucocorticoids by patients with adrenal insufficiency. Clinical Endocrinology.
Lamarca, A., Ronot, M., Moall, S., Crona, J., Opalinska, M., Lopez, C.,... Dromain, C. (2019). Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study. In NEUROENDOCRINOLOGY (pp. 137-137). BASEL: KARGER.
Graf, J., Pape, U.F., Jann, H., Denecke, T., Arsenic, R., Brenner, W.,... Prasad, V. (2019). Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging.
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Ridolfi, A.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study. (pp. 178-178).
Mirakhur, B., Pavel, M.E., Pommier, R.F., Fisher, G.A., Phan, A.T., Massien, C.,... Vinik, A. (2018). BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS. Endocrine Practice, 24(11), 948-962.
Atanasov, G., Tsvetkova, ., Struecker, B., Andreou, A., Bahra, M., Prasad, .,... Pascher, A. (2018). Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors. (pp. 148-148).
Crona, J., Lamarca, A., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study. (pp. 171-171).
Pavel, M.E., Denecke, T., Lahner, H., Hoersch, D., Rinke, A., Koch, A.,... Raderer, M. (2018). Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study. (pp. 202-202).
Dillon, J., Kulke, M., Warner, R., Bergsland, E., Welin, S., O'Dorisio, T.,... Pavel, M.E. (2018). Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome. (pp. 224-224).
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Herbst, F., Ridolfi, A.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).

Last updated on 2019-24-04 at 10:22